
    
      This is a prospective, multi-center, single-arm clinical investigation for evaluation of the
      safety and effectiveness of the MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve
      System in the Treatment of Severe Aortic Stenosis. The investigation has two phases.

      Phase I（FIM）：The FIM stage is a prospective, multicenter, single-arm observational clinical
      investigation, aiming to evaluate the feasibility and safety of the MicroPort™ CardioFlow
      VitaFlow™ Transcatheter Aortic Valve System. A total of 10 patients will be enrolled and
      30-day clinical outcomes will be collected.

      Phase II (Pivotal)：The pivotal stage is a prospective, multi-center, single-arm clinical
      investigation with the performance goal, aiming to evaluate the safety and effectiveness of
      MicroPort™ CardioFlow VitaFlow™ Transcatheter Aortic Valve System for the treatment of severe
      aortic stenosis. A total of 110 patients will be enrolled in 11 clinical centers across
      China. Clinical or telephone follow-up is scheduled at 30 days, 6 months, 12 months, and 2 to
      5 years annually post-procedure.
    
  